Archive for the 'Eli Lilly' Category

Eli Lilly news feed.

Pemextrexed Shows Promise in Peritoneal Mesothelioma: Presented at ECCO

Pemetrexed alone or in tandem with a platinum agent shows good overall response and disease control rates in patients with peritoneal mesothelioma (PM), according to data presented here at the 14th European Cancer Conference (ECCO). The study enrolled 109 patients with a histologic or cytologic diagnosis of peritoneal mesothelioma that was not amenable to curative

more

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

Eli Lilly and Company today announced that it has submitted an application with the European Medicines Agency (EMEA) for centralised review of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, for the first-line treatment of advanced non-small cell lung cancer (NSCLC). ALIMTA is currently indicated in more than 85 countries as a second-line, single agent

more

Lilly Delivers Promising Update to Wall Street on Strategic Priorities, Pipeline Progress and Earnings Guidance

Company Sets Clear Focus on Accelerating Sales Growth, Increasing Productivity, Bringing New Drugs to Market and Replenishing the Late-Stage Pipeline. Research and Development Efforts and Expanded Biotech Capabilities Continue to Fuel Strong Pipeline, with 30 Molecules Under Development, Including 10 Newly Announced. Lilly Reconfirms 2006 Sales and Earnings Guidance; Anticipates 2007 Sales Growth in the

more

Oncology Researchers Recognized as Heroes of Chemistry; American Chemical Society Honors Lilly and Princeton Scientists for Discovery of Therapy for Asbestos-Related Cancer

Three researchers who led the discovery and development of the first drug approved to treat malignant pleural mesothelioma (MPM), a cancer associated with exposure to asbestos, were named as Heroes of Chemistry by the American Chemical Society (ACS). Researchers Homer Pearce, Ph.D., Chuan (Joe) Shih, Ph.D., and Edward C. Taylor, Ph.D., led a long-standing collaboration

more

Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel; Alimta Also Shows Tolerability as Triplet Combination Treatment in First-Line Lung Cancer

Data presented today at the 42nd American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Ga., affirms that ALIMTA® (pemetrexed), manufactured and marketed by Eli Lilly and Company, offers patients with advanced non-small cell lung cancer (NSCLC) similar overall survival as docetaxel (Taxotere®). The survival data were part of a large (n=571), randomized Phase

more

Lilly Oncology Prepares for Strong Showing at ASCO 2006; Targets Breast Cancer and Other Tumors with 79 Studies: 11 breast cancer studies; 29 thoracic cancer studies; and 8 studies with developing targeted agent

Lilly Oncology, a global leader in thoracic cancer treatment, will be presenting important data on its emerging research in breast cancer therapy at the 42nd annual American Society for Clinical Oncology (ASCO) meeting in Atlanta, Ga., June 2-6, 2006. Among the 79 studies being presented by Lilly Oncology, data from 11 clinical studies focus on

more

Thoracic Cancer Patients Find New Reasons for Hope with Alimta®: New data may provide important treatment advances in mesothelioma and lung cancer

Patients with a cancer of the lining of the lung, known as malignant pleural mesothelioma (MPM), lived longer than previously reported(1), when treated with Eli Lilly and Company’s Alimta® (pemetrexed) in combination with cisplatin, according to updated data presented today at the 11th annual World Conference on Lung Cancer (WCLC). Alimta is the first and

more

Alimta Approved as First Licensed Treatment for Mesothelioma, a Deadly Cancer Caused by Asbestos

BASINGSTOKE, England, – Lilly UK announced today that Alimta ® (pemetrexed) will be available shortly for the treatment of people diagnosed with mesothelioma, a cancer of the lining of the lungs for which there is no known cure. Pemetrexed is the first licenced treatment for malignant pleural mesothelioma, in combination with cisplatin. Most mesothelioma patients

more

FDA Approves Lilly’s Alimta(R) (pemetrexed) for the Second-Line Treatment of Advanced Lung Cancer: Accelerated Approval Results in Second U.S. Indication in Six Months for Alimta

Today, Eli Lilly and Company’s anti-cancer drug Alimta® (pronounced: “uh-LIMB-ta”) received its second U.S. approval in 2004. The U.S. Food and Drug Administration granted accelerated approval for Alimta for the treatment of locally advanced or metastatic non-small cell lung cancer in previously treated patients. In February, Alimta was approved, in combination with cisplatin (a common

more

Alimta(R) Receives Positive Endorsement for Lung Cancer Approval from FDA Advisory Committee; Unanimous Endorsement for Accelerated Approval in Second-Line Non-Small Cell Lung Cancer

July 22, 2004. Eli Lilly and Company announced today that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer. “The committee’s unanimous recommendation is a major step forward for patients being treated for

more

Alimta® Receives CHMP Positive Opinion for Two Cancer Indications: Recommended for Approval to Treat Malignant Pleural Mesothelioma and Lung Cancer

INDIANAPOLIS, PRNewswire-FirstCall – Eli Lilly and Company (NYSE: LLY) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for dual cancer indications for pemetrexed. The CHMP has recommended to the European Commission that approval be granted for pemetrexed. If approved, this cancer therapy will be marketed

more

Pemetrexed (Alimta®) Study Suggests Advances over Docetaxel (Taxotere®) in Second-Line Non-Small Cell Lung Cancer; Currently, Taxotere® is the only drug approved in the U.S. for second-line treatment of patients with non-small cell lung cancer

In a recent study, Lilly’s drug pemetrexed showed a similar patient survival rate, but with an improved safety profile, when compared to docetaxel (Taxotere(R)), the current standard of care for second-line non-small cell lung cancer. The research findings of the largest head-to-head Phase III trial ever reported to date in second-line non-small cell lung cancer

more

Alimta® Compares Favorably to Taxotere® in the Second-Line Treatment of Non-Small Cell Lung Cancer; Currently, Taxotere® is the only drug approved in the U.S. for second-line treatment of patients with non-small cell lung cancer

May 4, 2004. Results of a global, phase III trial indicate that Alimta® (pemetrexed) produces a similar patient survival rate as Taxotere®, but with an improved safety profile in the second-line treatment of patients with non-small cell lung cancer (NSCLC). Taxotere® is currently the standard of care for second-line treatment of NSCLC. This study constituted

more

Puget Sound Cancer Centers Plays Significant Role in Clinical Testing Of Newly Approved Cancer Drug; FDA Approves Alimta for Treatment of Asbestos-Related Cancer

Puget Sound Cancer Centers was actively involved in the clinical testing for the new drug Alimta, the first approved treatment for asbestos-related cancer in patients who are not candidates for surgery. Alimta, developed by Eli Lilly and Company, recently received Food and Drug Administration approval for use in the treatment of malignant pleural mesothelioma, a

more

FDA Approves Alimta-Cisplatin Combination for Treatment of Asbestos-Related Cancer; The first and only drug regimen proven to help patients with an asbestos-related cancers like mesothelioma live longer

The first and only drug regimen proven to help patients with an asbestos-related cancer live longer was approved today by the U.S. Food and Drug Administration (FDA). Alimta® ("uh-LIMB-ta"), to be introduced shortly by Eli Lilly and Company (NYSE: LLY), was approved for use with cisplatin, a standard chemotherapy agent, for the treatment of malignant

more

Last update: April 01, 2019. 03:30:08 pm.